Arvinas (ARVN.US) Financial Statements - Balance Sheet/Income Statement/Cash Flow - Longbridge

Quote List Quote List

Event Tracking

Dec6

Arvinas Announces Support for ARV-393 and Glofitamab Combination Therapy for DLBCL and Plans Phase 1 Clinical Trial

13:05

Nov24

Arvinas Inc. to Present Multiple Abstracts on Vepdegestrant at San Antonio Breast Cancer Symposium

12:00

Nov5

TD Cowen Analyst Maintains Hold Rating on Arvinas Holding

18:27

Arvinas released FY2025 Q3 earnings on November 5, Pre-Market (EST), actual revenue USD 41.9 M (forecast USD 27.55 M), actual EPS USD -0.4795 (forecast USD -0.7166)

14:30

Arvinas released FY2025 9 Months earnings on November 5 Pre-Market (EST), actual revenue USD 253.1 M, actual EPS USD -0.1795

14:30

Arvinas Reports Q3 2025 Earnings

12:07

Schedules & Filings

Schedules

Filings

Nov5

Earning Release(EST)

FY2025 Q3 Earning Release (USD) Revenue 41.9 M, Net Income -35.1 M, EPS -0.4795

Aug6

Earning Release(EST)

FY2025 Q2 Earning Release (USD) Revenue 22.4 M, Net Income -61.2 M, EPS -0.84

May1

Earning Release(EST)

FY2025 Q1 Earning Release (USD) Revenue 188.8 M, Net Income 82.9 M, EPS 1.14

View More

Stock List

Top Gainers

Top Decliners

China Concepts

Symbol

Price

%Chg

Change

View More